Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study

OBJECTIVE: To assess the risk of adverse events associated with heterologous primary (two dose) and booster (three dose) vaccine schedules for covid-19 with Oxford-AstraZeneca’s ChAdOx1-S priming followed by mRNA vaccines (Pfizer-BioNTech’s BNT162b2 or Moderna’s mRNA-1273) as compared with homologou...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersson, Niklas Worm, Thiesson, Emilia Myrup, Laursen, Mona Vestergaard, Mogensen, Stine Hasling, Kjær, Jesper, Hviid, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277486/
https://www.ncbi.nlm.nih.gov/pubmed/35831006
http://dx.doi.org/10.1136/bmj-2022-070483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277486/
https://www.ncbi.nlm.nih.gov/pubmed/35831006
http://dx.doi.org/10.1136/bmj-2022-070483

Ejemplares similares